Ford Robert B 4

What Happened
Robert B. Ford, Abbott Laboratories' Chairman and CEO, acquired 18,800 shares in an open-market purchase on January 23, 2026. The reported weighted-average price was $107.13 per share, for a total transaction value of approximately $2,013,967. This was a purchase (often interpreted as a bullish signal), not a sale or option exercise.

Key Details

• Transaction date: 2026-01-23; Form 4 filed 2026-01-26 (filed within the required reporting window).
• Price: weighted average $107.13; individual trades ranged from $106.735 to $107.485 (footnote indicates multiple transactions and offers to provide per-price breakdown on request).
• Shares acquired: 18,800; total value ≈ $2,013,967.
• Ownership after transaction: not specified in the provided filing.
• Footnotes: F1 explains the weighted-average price and range of trade prices; F2 states the shares are held in the Ford Family Trust (dated June 2, 2014), of which Mr. Ford is co-trustee.

Context
This was an open-market purchase credited to a family trust rather than a grant or option exercise. Purchases by executives can attract attention from investors as a sign of insider buying, but filings alone do not reveal the insider’s motivations.